Silo Pharma Inc. (NASDAQ: SILO) announced today that its wholly owned subsidiary, QwikAgents, has been accepted into Advanced Micro Devices' AMD AI Developer Program, providing access to AMD Developer Cloud credits, AI development tools, training resources and a global developer community. The company said the program is expected to accelerate development, testing, optimization and deployment of its AI agent platform across consumer and enterprise applications.
QwikAgents is developing a platform that enables users to deploy persistent AI agents for tasks including research, content generation, scheduling, coding and workflow automation. Silo said participation in the AMD AI Developer Program is expected to support platform performance, agent reliability and scalable deployment as QwikAgents expands its capabilities for individuals, developers, small businesses and enterprise customers.
The acceptance into the AMD AI Developer Program marks a significant milestone for QwikAgents, as it provides access to cutting-edge AI development resources. By leveraging AMD's cloud credits, QwikAgents can test and optimize its AI agents on high-performance computing infrastructure, potentially reducing development time and improving agent responsiveness. The program also offers training resources that could help QwikAgents refine its models for better accuracy and efficiency.
For Silo Pharma, which is primarily known as a developmental-stage biopharmaceutical company focusing on stress-induced psychiatric disorders, chronic pain, and CNS diseases, the QwikAgents subsidiary represents a diversification into AI technology. The company's portfolio includes programs such as SPC-15 for PTSD and SP-26 for fibromyalgia. The collaboration with AMD through this developer program could enhance the value of QwikAgents' platform, potentially opening new revenue streams for Silo.
The news comes as AI agents gain traction across industries for automating complex tasks. QwikAgents' platform aims to simplify the deployment of AI agents that can operate continuously, handling tasks like research and scheduling without human intervention. With AMD's support, the platform could achieve higher performance and reliability, making it more competitive against other AI agent solutions.
For more information, visit the full press release at https://ibn.fm/313SC. Additional updates on Silo Pharma are available in the company's newsroom at https://ibn.fm/SILO.
